Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Huan-Ying Wan"'
Autor:
Peng Wu, Yi-qun Jiang, Feng-li Si, Huan-ying Wang, Xiao-bo Song, Chun-feng Sheng, Xun Xu, Fan Li, Jing Zhang
Publikováno v:
npj Primary Care Respiratory Medicine, Vol 34, Iss 1, Pp 1-10 (2024)
Abstract This study aimed to investigate the real-world standardisation and adherence of medical treatment regimens in patients with chronic obstructive pulmonary disease (COPD) in the community for making future management strategy. The follow-up da
Externí odkaz:
https://doaj.org/article/5d5cb708d2d844e0bb3fdadf4f0a184d
Autor:
Jian Kang, Na Hu, Yong Lin, Lin Su, Haoyan Wang, Ping Chen, Huan-Ying Wan, Meiling Jin, Qianli Ma, Jiangtao Lin, Shuang Liu, Qinglin Hao
Publikováno v:
Allergy, Asthma & Immunology Research
PURPOSE: Asthma affects approximately 30 million patients in China; however, tiotropium data for Chinese patients is limited. This study aimed to assess the efficacy and safety of tiotropium in Chinese patients with moderate symptomatic asthma. METHO
Autor:
Zi Lai Pan, Yong Li, Shao-guang Huang, Ting Cheng, Huan Ying Wan, Qing Yun Li, Qi Jian Cheng, Guo Chao Shi, Shuai Pang
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Ting Cheng,1–3 Yong Li,1,3 Shuai Pang,1 Huan Ying Wan,1,3 Guo Chao Shi,3,4 Qi Jian Cheng,1,3 Qing Yun Li,3,4 Zi Lai Pan,5 Shao Guang Huang3,4 1Department of Respiratory Medicine, Ruijin Hospital North, Shanghai Jiao Tong University School of Medici
Autor:
Huan Ying Wan, Shu Yi Gu, Qing Yun Li, Ji Min Shen, Lei Ren, Wei Wu Deng, Xian Wen Sun, Shaoguang Huang
Publikováno v:
The American Journal of the Medical Sciences. 349:228-233
Background Heterogeneity of clinical presentation of chronic obstructive pulmonary disease (COPD) attributes to different pathological basis. High-resolution computed tomography (HRCT) phenotypes of COPD may reflex the pathological basis of COPD indi
Autor:
Jinping Zheng, Chunxue Bai, Jian Kang, Marco Sardina, Nanshan Zhong, Xia Li, Bai-Song Wang, Yi Gao, Huan-Ying Wan, Lijun Ma, Fuqiang Wen, Ping Chen, Wanzhen Yao, Luca Raiteri
Publikováno v:
The Lancet Respiratory Medicine. 2:187-194
Summary Background Increased oxidative stress and inflammation has a role in the pathogenesis of chronic obstructive pulmonary disease (COPD). Drugs with antioxidant and anti-inflammatory properties, such as N-acetylcysteine, might provide a useful t
Autor:
Yi Xiang, Huan-Ying Wan, Rong-Xin Zhang, Zhaohui Gu, Bing Han, Cui-Xia Zheng, Xia Chen, Xia-Jun Rong, Qingyun Li, Chun-Ming Pan
Publikováno v:
International Journal of Oncology. 43:755-764
Squamous cell lung cancer is a major histotype of non-small cell lung cancer (NSCLC) that is distinct from lung adenocarcinoma. We used whole-exome sequencing to identify novel non-synonymous somatic mutations in squamous cell lung cancer. We identif
Publikováno v:
Clinical science (London, England : 1979). 130(21)
Previous studies have shown that the RAS (renin–angiotensin system) might participate in airway remodelling in asthma. As a main component of the RAS, Ang-(1–7) [angiotensin-(1–7)] has been reported in few studies regarding its protective effec
Autor:
Xiang Zhou, Bing Han, Huai-Dong Song, Wang-Fu Zang, Rong-Xin Zhang, Cui-Xia Zheng, Zhong-Yuan Chen, Huan-Ying Wan
Publikováno v:
Oncology Letters. 2:1233-1237
Mutations of the epidermal growth factor receptor (EGFR) in patients with non-small cell lung cancer (NSCLC) were identified by re-sequencing all exons of this gene to evaluate the frequencies of EGFR gene mutation and identify rare or novel EGFR mut
Publikováno v:
Sleep and Breathing. 13:289-293
The study was designed to analyze body mass index (BMI) as one of risk factors for snoring in Chinese women.Totally, 2,938 women (2,423 available for evaluation of menstrual status) aged over 30 years from a population-based epidemiologic study were
Autor:
Meilin Liao, Teena M. West, Huan-ying Wan, Belinda J. Hall, Long-yun Li, Li Wang, Shiying Yu, Yun-zhong Zhu
Publikováno v:
Chinese Medical Journal. 121:892-897
Background Gemcitabine plus cisplatin is a standard treatment for stages IIIB and IV nonsmall cell lung cancer (NSCLC). This randomized phase II study evaluated a 3-week versus a 4-week schedule of gemcitabine-cisplatin as first line treatment for Ch